Richard Daniell Sells 17,295 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 17,295 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the sale, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Richard Daniell also recently made the following trade(s):

• On Tuesday, December 9th, Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24.

Teva Pharmaceutical Industries Trading Up 0.0%

Shares of TEVA opened at $31.51 on Wednesday. The business’s 50-day moving average price is $33.01 and its 200 day moving average price is $26.50. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $36.23 billion, a P/E ratio of 26.26, a P/E/G ratio of 10.54 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the prior year, the firm earned $0.71 earnings per share. The business’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Recent quarterly results and FY‑2026 guidance remain supportive — Teva reported a Q4 EPS and revenue beat and set FY‑2026 EPS guidance of 2.570–2.770, with y/y revenue growth (~11.4%), which underpins investor confidence and helps explain upward pressure on the shares. MarketBeat TEVA coverage
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Scotiabank, Barclays, Truist, Goldman Sachs, others) have raised targets and ratings this quarter, boosting buy-side interest and supporting the stock’s gain.
• Neutral Sentiment: Management presentations at conferences — transcripts from the Leerink and Barclays healthcare conferences are now available; investors will scan these for pipeline updates, margin/cost commentary and capital‑allocation signals but they’ve not yet produced major new guidance. Leerink transcript Barclays transcript
• Negative Sentiment: Concentrated insider selling disclosed (filings show March 5 trades) — multiple senior executives sold shares at an average price of ~$31.67, including CEO Richard D. Francis (20,025 shares) and several EVPs; such sizable, coordinated disclosures can weigh on sentiment even if sales are routine or pre‑planned. Example SEC filing (CEO sale)
• Negative Sentiment: Media reports amplifying insider sales — outlets flagged the CEO and other executive sales, which can increase investor caution and short‑term volatility even when fundamentals remain solid. Media coverage of insider sales

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TEVA shares. Truist Financial raised their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Bank of America lifted their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.67.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $25,000. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the second quarter worth approximately $41,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.